Aorta
Endovascular

Treatment of recurrent endoleak type II

Type II endoleaks after EVAR are usually harmless and often resolve on their own. But in this case, an 80-year-old patient faces a stubborn recurrence: his aneurysm sac continues to expand despite previous interventions.

Follow this case to understand the challenges of identifying feeding vessels, planning embolisation strategies, and deciding when further treatment is warranted.

Hospital Universitario de Jaén, Spain
Part I - Case presentation

Introduction

  • Type 2 endoleaks (EL2) after EVAR are common with self-limiting behaviour in most cases.
  • According to current guidelines, treatment is conservative. The intervention is indicated only with expansion of the sac ≥ 5mm.
  • Different approaches for embolisation have been used and, despite high technical success, recurrence is not uncommon and many patients require multiple interventions.
Recurrent endoleak type II

Clinical presentation

  • Our patient is an 80-year-old male.
  • Medical history:
    • Atrial fibrillation
    • Hypertension.
    • Ischemic heart disease.
    • COPD

In May 2022: EVAR for a 52 mm infrarenal AAA with Ovation ALTO and right renal polar embolisation.

Recurrent endoleak type II: EVAR for 52mm infrarenal AAA with Ovation ALTO with right renal polar embolization.

In October 2022: follow-up with EL2 and sac growth (57 mm). 

Recurrent endoleak type II: Follow-up with EL2 and sac growth (57mm).

In July 2023: angiography with selective catheterisation of the superior mesenteric artery, without identifying contact with the Arc of Riolan or direct connection with the inferior mesenteric artery. 

Right hypogastric catheterisation, identifying branch that connects with median sacral, without being able to catheterise it.

On angio-CT 2024: persistence of EL2, with sac growth (59 mm).

What will happen next?

Powered by Quiz Maker